ICSR (individual case safety report)
•Download as PPTX, PDF•
7 likes•4,673 views
The document discusses individual case safety reports (ICSRs) and the process for reporting adverse drug reactions (ADRs). An ICSR contains identifiable information about the reporter, patient, suspected adverse event, and suspected medicinal product. The steps for reporting include ICSR collection, processing, data entry, quality review, and medical review. Key requirements are that an ICSR contains identifiable information on the reporter, patient, suspected ADR, and suspected product to allow for reporting of ADRs occurring in single patients.
Report
Share
Report
Share
Recommended
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’SRaghavendra institute of pharmaceutical education and research .
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
Definitions, Severity assessment, Seriousness assessment
Naranjo algorithm, Preventability assessment
By
Ms. B. Mary Vishali
Department of Pharmacology
History of Pharmacovigilance
Concept of Pharmacovigilance, history and development of pharmacovigilance, WHO International drug monitoring programme, Pharmacovigilance programme of India
Pharmacovigilance programme of india
it is about the Pharmocvigilance progamme of India with its background and current scenario with the detail about vigiflow and vigibase
Causality Assessment ADR.pdf
This document discusses different methods for assessing the causality of adverse drug reactions (ADRs). It describes three main types of methods: 1) Expert opinion or clinical judgment methods like the WHO causality assessment scale, 2) Algorithmic methods like the Naranjo scale that use questionnaires and scoring systems, 3) Probabilistic or Bayesian methods that calculate the probability of drug causation based on prior probabilities. The WHO scale and Naranjo scale are discussed in detail as examples of each method.
History and progress of pharmacovigilance
About the history and progression of pharmacovigilance (monitoring of ADR's in phase 4 clinical trials/ post markrting surveillance )
Severity, seriousness, predictability and preventability assessment
This document discusses the assessment of severity and seriousness of adverse drug reactions (ADRs). It defines severity as the intensity of a medical event, categorizing ADRs as mild, moderate or severe based on management steps. It also describes several classification scales for ADR severity, including one by Karch and Lasagna and the Modified Hartwig's and Siegel Scale. The document defines seriousness classification according to regulatory criteria. It then discusses preventability and predictability of ADRs, describing scales by Schumock and Thornton for preventability and the distinction between Type A and Type B reactions in terms of predictability.
Establishment of Pharmacovigilance Programme
1. Pharmacovigilance
2. Pathway of PvPI
3. Establishment of PV Programme
in Hospital
4. Establishment of PV Programme
in Industry
5. Contract Research Organization
6. Establishment a National Programme
Establishing Pharmacovigilance Centres In Hospital.pptx
The document discusses establishing pharmacovigilance centers in hospitals to monitor adverse drug reactions. It outlines the steps to set up a center, including obtaining approvals, designing reporting forms, educating staff, and establishing infrastructure for data collection and analysis. Key requirements for an effective center include adequate trained staff, proper facilities, communication systems, and a sustainable source of funding. The center would operate by collecting ADR reports from healthcare professionals and entering the data into a database to help detect safety issues and inform regulation.
Recommended
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’SRaghavendra institute of pharmaceutical education and research .
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
Definitions, Severity assessment, Seriousness assessment
Naranjo algorithm, Preventability assessment
By
Ms. B. Mary Vishali
Department of Pharmacology
History of Pharmacovigilance
Concept of Pharmacovigilance, history and development of pharmacovigilance, WHO International drug monitoring programme, Pharmacovigilance programme of India
Pharmacovigilance programme of india
it is about the Pharmocvigilance progamme of India with its background and current scenario with the detail about vigiflow and vigibase
Causality Assessment ADR.pdf
This document discusses different methods for assessing the causality of adverse drug reactions (ADRs). It describes three main types of methods: 1) Expert opinion or clinical judgment methods like the WHO causality assessment scale, 2) Algorithmic methods like the Naranjo scale that use questionnaires and scoring systems, 3) Probabilistic or Bayesian methods that calculate the probability of drug causation based on prior probabilities. The WHO scale and Naranjo scale are discussed in detail as examples of each method.
History and progress of pharmacovigilance
About the history and progression of pharmacovigilance (monitoring of ADR's in phase 4 clinical trials/ post markrting surveillance )
Severity, seriousness, predictability and preventability assessment
This document discusses the assessment of severity and seriousness of adverse drug reactions (ADRs). It defines severity as the intensity of a medical event, categorizing ADRs as mild, moderate or severe based on management steps. It also describes several classification scales for ADR severity, including one by Karch and Lasagna and the Modified Hartwig's and Siegel Scale. The document defines seriousness classification according to regulatory criteria. It then discusses preventability and predictability of ADRs, describing scales by Schumock and Thornton for preventability and the distinction between Type A and Type B reactions in terms of predictability.
Establishment of Pharmacovigilance Programme
1. Pharmacovigilance
2. Pathway of PvPI
3. Establishment of PV Programme
in Hospital
4. Establishment of PV Programme
in Industry
5. Contract Research Organization
6. Establishment a National Programme
Establishing Pharmacovigilance Centres In Hospital.pptx
The document discusses establishing pharmacovigilance centers in hospitals to monitor adverse drug reactions. It outlines the steps to set up a center, including obtaining approvals, designing reporting forms, educating staff, and establishing infrastructure for data collection and analysis. Key requirements for an effective center include adequate trained staff, proper facilities, communication systems, and a sustainable source of funding. The center would operate by collecting ADR reports from healthcare professionals and entering the data into a database to help detect safety issues and inform regulation.
Spontaneous Reporting System
The spontaneous reporting system is a passive surveillance system where health professionals voluntarily report adverse drug reactions directly to regulatory authorities or pharmaceutical companies. It involves 3 main processes: 1) data acquisition from reported cases, 2) data assessment of individual cases and pooled data, and 3) data interpretation to generate safety signals. Countries have different reporting forms, like the Yellow Card used in the UK since 1964. Factors like educational campaigns and inclusion of reporting options in prescription pads have helped increase reporting rates in the UK. India's Pharmacovigilance Programme similarly encourages voluntary reporting of all suspected adverse reactions via established adverse drug monitoring centers.
ICH Guidelines for Pharmacovigilance
Organization and objectives of ICH, expedited reporting, ICSR, PSURs, post approval expedited reporting, pharmacovigilance Planning, good clinical practices
Pharmacovigilance
by Dr. Vishal Pawar
MD Pharmacology
a complete and comprehensive view of Pharmacovigilance around the world and in india
WHO International Drug Monitoring Program
The WHO International Drug Monitoring Program was established in 1963 in response to the thalidomide disaster. It currently has 143 member countries that submit adverse drug reaction reports to the global pharmacovigilance database VigiBase managed by the Uppsala Monitoring Centre (UMC) as a WHO collaborating center. The UMC analyzes VigiBase data to identify new safety signals, conducts research, and provides tools and training to support member countries' pharmacovigilance activities. The overall goals are to identify unknown adverse drug reactions and ensure medicines are used safely worldwide.
Detection, reporting and management of adverse events
This document discusses adverse drug reactions (ADRs), including definitions, classifications, detection, reporting, and management. It notes that ADRs are a major clinical problem that can cause suffering and increased healthcare costs. It emphasizes the importance of monitoring and reporting ADRs to improve patient safety. Pharmacists can play an important role by monitoring high-risk patients and drugs, educating on ADR reporting, and assisting in the detection and assessment of ADRs. Timely reporting of ADRs is crucial to help prevent human suffering and unnecessary costs from drug-related injuries.
Regulatory terminologies used in PV (Pharmacovigilance)
This document defines various regulatory terminologies used in pharmacovigilance (PV). It defines key terms like pharmacovigilance, adverse drug reactions, clinical trials, causality assessment, and data mining. It also provides definitions for terms related to evaluating drug safety like absolute risk, incidence, benefits, harms, and effectiveness/risk analysis. Regulatory organizations involved in PV like CIOMS, ICH, and MedDRA are also defined.
Methods of causality assessment
This document discusses various methods used to assess causality in pharmacovigilance. It describes three broad categories of causality assessment methods: expert judgment, algorithms, and probabilistic/Bayesian approaches. For algorithms, it provides examples like the French method, Kramer method, and Naranjo scale. It also discusses some probabilistic methods like the Australian method and Bayesian Adverse Reactions Diagnostic Instrument (BARDI). Overall, the document provides an overview of the different existing approaches for determining if a suspected adverse drug reaction is actually caused by the drug in question.
Detection and Reporting of Adverse Reaction
This document discusses pharmacovigilance and adverse drug reaction reporting. It covers several topics: methods of detecting ADRs like pre-marketing safety evaluation, post-marketing surveillance, and causality assessment; communicating ADR information to health professionals; and methods for reporting ADRs like spontaneous reporting and standardized case report forms. The key aspects of ADR reporting include who should report, what to report, and where to send reports for evaluation. Accurate documentation of patient information, suspected drugs, and reactions is important for assessment.
Pharmacovigilance
This document discusses pharmacovigilance, which involves monitoring the safety of drugs after they have been approved. It defines pharmacovigilance and explains why it is needed given limitations of clinical trials. It describes types of adverse drug reactions and how they are classified. It outlines the goals and processes of pharmacovigilance programs, including reporting adverse reactions, conducting causality assessments, and submitting periodic safety update reports. The overall aim is to ensure safe and effective use of medicines through continual monitoring and regulatory action.
PSUR
The document provides information on periodic safety update reports (PSURs), including:
- PSURs are intended to evaluate the risk-benefit balance of a drug based on new or changing information during the post-approval phase.
- The objectives of a PSUR are to examine if new safety information aligns with previous knowledge, summarize relevant new safety data that could impact risk-benefit analysis, and provide an integrated risk-benefit evaluation.
- Guidelines for PSURs are provided in the ICH E2C guideline and EU's GVP Module VII, with the format and content changing to focus more on risk-benefit analyses and summary tables rather than individual case reports.
Safety data generation in PV.pptx
This document discusses the generation of safety data at different phases of drug development and use. In pre-clinical phases, exploratory toxicology studies provide initial data on toxicity in organs and systems. Regulatory toxicology studies follow GLP standards and include acute toxicity, chronic toxicity, and reproductive toxicity tests over periods of 28 days to 24 months in two animal species. Clinical trial phases involve monitoring and reporting adverse events and serious adverse events in subjects. Post-marketing safety data comes from periodic safety update reports, adverse event reports from healthcare providers and patients, and analysis of safety issues emerging after approval and wider use.
WHO international drug monitoring programme.pptx
The WHO International Drug Monitoring Program was established in 1963 in response to the thalidomide disaster. It aims to collect reports of adverse drug reactions from member countries. The program has grown from 10 founding members to 143 member countries currently. Countries submit individual case safety reports to the global Vigibase database managed by the Uppsala Monitoring Centre in Sweden, a WHO collaborating center. The program identifies new safety issues, facilitates information exchange between countries, and provides tools and training to support pharmacovigilance systems globally.
Pharmacovigilance methods
Active Surveillance, Passive Surveillance, Comparative observational methods, stimulated reporting, targeted clinical investigations
Terms used in pharmacovigilance
1) The document defines many terms used in pharmacovigilance, including adverse event, adverse reaction, causality assessment, signal, and serious adverse reaction.
2) An adverse event is any untoward medical occurrence during treatment but not necessarily caused by the treatment, while an adverse reaction is characterized by a suspected causal relationship to the treatment.
3) A signal refers to reported information about a potential causal relationship between an adverse event and drug that was previously unknown or incompletely documented.
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
International Nonproprietary Names (INNs) provide a unique name for each pharmaceutical substance to aid clear identification and safe use worldwide. The WHO manages the INN system, selecting names through a process involving proposed names, an objection period, and final recommended INNs. INNs aim to identify substances uniquely while avoiding names that could cause confusion or be proprietary. Principles for selection include being distinctive, concise, and avoiding confusion with other names. Stem elements are often used to group related substances.
CIOMS (1).pptx
This presentation gives a brief knowledge of CIOMS, its history, missions and collaborations of CIOMS. This presentation also contains CIOMS organizational structure, detailed knowledge of CIOMS Former and Present Working Groups. This will also guide about CIOMS form, its reporting and details to be filled while reporting an ADR.
Vaccine safety surveillance
This document discusses vaccine safety surveillance systems. It describes post-marketing surveillance systems like VAERS in the US and EudraVigilance in Europe that monitor adverse events. International organizations like WHO and programs like EPI work to strengthen safety surveillance globally and help low-income countries monitor vaccines. Harmonized reporting systems, guidelines, and data sharing aim to ensure vaccine safety worldwide.
Institutional review board by akshdeep sharma
The Institutional Review Board/Independent Ethics Committee (IRB/IEC) serves as an independent body that reviews and approves clinical trials to protect participant safety and rights. The IRB/IEC consists of at least five members with diverse qualifications to evaluate scientific and ethical aspects of trials. The IRB/IEC's responsibilities include reviewing trials, providing continuing oversight, ensuring informed consent, and maintaining records for regulatory review.
Med dra Basics
This document provides an introduction and overview of MedDRA, the medical terminology used for medical coding in the pharmaceutical industry. It discusses the history and development of MedDRA, which originated from the need for a single, standardized terminology to classify medical information for regulatory purposes. The document outlines the requirements for MedDRA, how it addresses issues with prior terminologies, and its scope and uses in clinical research and by regulatory authorities. It also provides examples of the structural elements of MedDRA and how it has been expanded over multiple versions to include more terms and enhance functionality.
Narrative Writing
Narrative writing is a form of writing that tells a story or describes a sequence of events. Narrative writing can take many forms, including novels, short stories, memoirs, personal essays, and even scientific or clinical case reports. The following are some key elements of narrative writing:
Plot: The plot is the sequence of events that make up the story. It includes the exposition, rising action, climax, falling action, and resolution. The plot should be well-structured and engaging, with a clear beginning, middle, and end.
Characters: The characters are the people, animals, or other beings that are involved in the story. Characters should be well-developed and believable, with their own personalities, motivations, and conflicts.
Setting: The setting is the time and place in which the story takes place. The setting should be described in detail, with attention paid to the sights, sounds, smells, and other sensory details that create a sense of atmosphere.
Point of view: The point of view is the perspective from which the story is told. It can be first-person (using "I" or "we"), second-person (using "you"), or third-person (using "he," "she," or "they"). The point of view should be consistent throughout the story.
Theme: The theme is the central idea or message of the story. It can be implicit or explicit, and may explore universal themes such as love, loss, or redemption.
Collection, Processing and Reporting of ICSR
ICSR (Individual Case Safety Report) is a critical component of pharmacovigilance, which involves the collection, processing, and reporting of adverse events associated with the use of drugs and other medical products.
The collection of ICSRs involves the systematic and proactive collection of adverse event data from a variety of sources, including healthcare professionals, patients, and regulatory authorities. The process typically involves the use of standardized reporting forms, which capture information about the patient, the drug product, and the adverse event. In addition to spontaneous reporting, ICSRs may also be collected through clinical trials, post-authorization safety studies, and other surveillance programs.
Once an ICSR is received, it is subjected to a process of validation and assessment to ensure that it is complete and of sufficient quality to be included in the pharmacovigilance database. This involves checking that the report contains all the required information and that it is consistent with known safety profiles of the drug product.
After validation, the ICSR is coded according to standard medical dictionaries, such as MedDRA (Medical Dictionary for Regulatory Activities), which allows for consistent and accurate reporting of adverse events across different products and databases. The data is then entered into the pharmacovigilance database, where it is analyzed for potential safety signals or trends.
Reporting of ICSRs is an essential component of pharmacovigilance, and regulatory authorities require that pharmaceutical companies report adverse events associated with their products in a timely and accurate manner. The process of reporting typically involves the submission of periodic safety update reports, as well as ad-hoc reports for significant safety events.
More Related Content
What's hot
Spontaneous Reporting System
The spontaneous reporting system is a passive surveillance system where health professionals voluntarily report adverse drug reactions directly to regulatory authorities or pharmaceutical companies. It involves 3 main processes: 1) data acquisition from reported cases, 2) data assessment of individual cases and pooled data, and 3) data interpretation to generate safety signals. Countries have different reporting forms, like the Yellow Card used in the UK since 1964. Factors like educational campaigns and inclusion of reporting options in prescription pads have helped increase reporting rates in the UK. India's Pharmacovigilance Programme similarly encourages voluntary reporting of all suspected adverse reactions via established adverse drug monitoring centers.
ICH Guidelines for Pharmacovigilance
Organization and objectives of ICH, expedited reporting, ICSR, PSURs, post approval expedited reporting, pharmacovigilance Planning, good clinical practices
Pharmacovigilance
by Dr. Vishal Pawar
MD Pharmacology
a complete and comprehensive view of Pharmacovigilance around the world and in india
WHO International Drug Monitoring Program
The WHO International Drug Monitoring Program was established in 1963 in response to the thalidomide disaster. It currently has 143 member countries that submit adverse drug reaction reports to the global pharmacovigilance database VigiBase managed by the Uppsala Monitoring Centre (UMC) as a WHO collaborating center. The UMC analyzes VigiBase data to identify new safety signals, conducts research, and provides tools and training to support member countries' pharmacovigilance activities. The overall goals are to identify unknown adverse drug reactions and ensure medicines are used safely worldwide.
Detection, reporting and management of adverse events
This document discusses adverse drug reactions (ADRs), including definitions, classifications, detection, reporting, and management. It notes that ADRs are a major clinical problem that can cause suffering and increased healthcare costs. It emphasizes the importance of monitoring and reporting ADRs to improve patient safety. Pharmacists can play an important role by monitoring high-risk patients and drugs, educating on ADR reporting, and assisting in the detection and assessment of ADRs. Timely reporting of ADRs is crucial to help prevent human suffering and unnecessary costs from drug-related injuries.
Regulatory terminologies used in PV (Pharmacovigilance)
This document defines various regulatory terminologies used in pharmacovigilance (PV). It defines key terms like pharmacovigilance, adverse drug reactions, clinical trials, causality assessment, and data mining. It also provides definitions for terms related to evaluating drug safety like absolute risk, incidence, benefits, harms, and effectiveness/risk analysis. Regulatory organizations involved in PV like CIOMS, ICH, and MedDRA are also defined.
Methods of causality assessment
This document discusses various methods used to assess causality in pharmacovigilance. It describes three broad categories of causality assessment methods: expert judgment, algorithms, and probabilistic/Bayesian approaches. For algorithms, it provides examples like the French method, Kramer method, and Naranjo scale. It also discusses some probabilistic methods like the Australian method and Bayesian Adverse Reactions Diagnostic Instrument (BARDI). Overall, the document provides an overview of the different existing approaches for determining if a suspected adverse drug reaction is actually caused by the drug in question.
Detection and Reporting of Adverse Reaction
This document discusses pharmacovigilance and adverse drug reaction reporting. It covers several topics: methods of detecting ADRs like pre-marketing safety evaluation, post-marketing surveillance, and causality assessment; communicating ADR information to health professionals; and methods for reporting ADRs like spontaneous reporting and standardized case report forms. The key aspects of ADR reporting include who should report, what to report, and where to send reports for evaluation. Accurate documentation of patient information, suspected drugs, and reactions is important for assessment.
Pharmacovigilance
This document discusses pharmacovigilance, which involves monitoring the safety of drugs after they have been approved. It defines pharmacovigilance and explains why it is needed given limitations of clinical trials. It describes types of adverse drug reactions and how they are classified. It outlines the goals and processes of pharmacovigilance programs, including reporting adverse reactions, conducting causality assessments, and submitting periodic safety update reports. The overall aim is to ensure safe and effective use of medicines through continual monitoring and regulatory action.
PSUR
The document provides information on periodic safety update reports (PSURs), including:
- PSURs are intended to evaluate the risk-benefit balance of a drug based on new or changing information during the post-approval phase.
- The objectives of a PSUR are to examine if new safety information aligns with previous knowledge, summarize relevant new safety data that could impact risk-benefit analysis, and provide an integrated risk-benefit evaluation.
- Guidelines for PSURs are provided in the ICH E2C guideline and EU's GVP Module VII, with the format and content changing to focus more on risk-benefit analyses and summary tables rather than individual case reports.
Safety data generation in PV.pptx
This document discusses the generation of safety data at different phases of drug development and use. In pre-clinical phases, exploratory toxicology studies provide initial data on toxicity in organs and systems. Regulatory toxicology studies follow GLP standards and include acute toxicity, chronic toxicity, and reproductive toxicity tests over periods of 28 days to 24 months in two animal species. Clinical trial phases involve monitoring and reporting adverse events and serious adverse events in subjects. Post-marketing safety data comes from periodic safety update reports, adverse event reports from healthcare providers and patients, and analysis of safety issues emerging after approval and wider use.
WHO international drug monitoring programme.pptx
The WHO International Drug Monitoring Program was established in 1963 in response to the thalidomide disaster. It aims to collect reports of adverse drug reactions from member countries. The program has grown from 10 founding members to 143 member countries currently. Countries submit individual case safety reports to the global Vigibase database managed by the Uppsala Monitoring Centre in Sweden, a WHO collaborating center. The program identifies new safety issues, facilitates information exchange between countries, and provides tools and training to support pharmacovigilance systems globally.
Pharmacovigilance methods
Active Surveillance, Passive Surveillance, Comparative observational methods, stimulated reporting, targeted clinical investigations
Terms used in pharmacovigilance
1) The document defines many terms used in pharmacovigilance, including adverse event, adverse reaction, causality assessment, signal, and serious adverse reaction.
2) An adverse event is any untoward medical occurrence during treatment but not necessarily caused by the treatment, while an adverse reaction is characterized by a suspected causal relationship to the treatment.
3) A signal refers to reported information about a potential causal relationship between an adverse event and drug that was previously unknown or incompletely documented.
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
International Nonproprietary Names (INNs) provide a unique name for each pharmaceutical substance to aid clear identification and safe use worldwide. The WHO manages the INN system, selecting names through a process involving proposed names, an objection period, and final recommended INNs. INNs aim to identify substances uniquely while avoiding names that could cause confusion or be proprietary. Principles for selection include being distinctive, concise, and avoiding confusion with other names. Stem elements are often used to group related substances.
CIOMS (1).pptx
This presentation gives a brief knowledge of CIOMS, its history, missions and collaborations of CIOMS. This presentation also contains CIOMS organizational structure, detailed knowledge of CIOMS Former and Present Working Groups. This will also guide about CIOMS form, its reporting and details to be filled while reporting an ADR.
Vaccine safety surveillance
This document discusses vaccine safety surveillance systems. It describes post-marketing surveillance systems like VAERS in the US and EudraVigilance in Europe that monitor adverse events. International organizations like WHO and programs like EPI work to strengthen safety surveillance globally and help low-income countries monitor vaccines. Harmonized reporting systems, guidelines, and data sharing aim to ensure vaccine safety worldwide.
Institutional review board by akshdeep sharma
The Institutional Review Board/Independent Ethics Committee (IRB/IEC) serves as an independent body that reviews and approves clinical trials to protect participant safety and rights. The IRB/IEC consists of at least five members with diverse qualifications to evaluate scientific and ethical aspects of trials. The IRB/IEC's responsibilities include reviewing trials, providing continuing oversight, ensuring informed consent, and maintaining records for regulatory review.
Med dra Basics
This document provides an introduction and overview of MedDRA, the medical terminology used for medical coding in the pharmaceutical industry. It discusses the history and development of MedDRA, which originated from the need for a single, standardized terminology to classify medical information for regulatory purposes. The document outlines the requirements for MedDRA, how it addresses issues with prior terminologies, and its scope and uses in clinical research and by regulatory authorities. It also provides examples of the structural elements of MedDRA and how it has been expanded over multiple versions to include more terms and enhance functionality.
What's hot (20)
Detection, reporting and management of adverse events
Detection, reporting and management of adverse events
Regulatory terminologies used in PV (Pharmacovigilance)
Regulatory terminologies used in PV (Pharmacovigilance)
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
Similar to ICSR (individual case safety report)
Narrative Writing
Narrative writing is a form of writing that tells a story or describes a sequence of events. Narrative writing can take many forms, including novels, short stories, memoirs, personal essays, and even scientific or clinical case reports. The following are some key elements of narrative writing:
Plot: The plot is the sequence of events that make up the story. It includes the exposition, rising action, climax, falling action, and resolution. The plot should be well-structured and engaging, with a clear beginning, middle, and end.
Characters: The characters are the people, animals, or other beings that are involved in the story. Characters should be well-developed and believable, with their own personalities, motivations, and conflicts.
Setting: The setting is the time and place in which the story takes place. The setting should be described in detail, with attention paid to the sights, sounds, smells, and other sensory details that create a sense of atmosphere.
Point of view: The point of view is the perspective from which the story is told. It can be first-person (using "I" or "we"), second-person (using "you"), or third-person (using "he," "she," or "they"). The point of view should be consistent throughout the story.
Theme: The theme is the central idea or message of the story. It can be implicit or explicit, and may explore universal themes such as love, loss, or redemption.
Collection, Processing and Reporting of ICSR
ICSR (Individual Case Safety Report) is a critical component of pharmacovigilance, which involves the collection, processing, and reporting of adverse events associated with the use of drugs and other medical products.
The collection of ICSRs involves the systematic and proactive collection of adverse event data from a variety of sources, including healthcare professionals, patients, and regulatory authorities. The process typically involves the use of standardized reporting forms, which capture information about the patient, the drug product, and the adverse event. In addition to spontaneous reporting, ICSRs may also be collected through clinical trials, post-authorization safety studies, and other surveillance programs.
Once an ICSR is received, it is subjected to a process of validation and assessment to ensure that it is complete and of sufficient quality to be included in the pharmacovigilance database. This involves checking that the report contains all the required information and that it is consistent with known safety profiles of the drug product.
After validation, the ICSR is coded according to standard medical dictionaries, such as MedDRA (Medical Dictionary for Regulatory Activities), which allows for consistent and accurate reporting of adverse events across different products and databases. The data is then entered into the pharmacovigilance database, where it is analyzed for potential safety signals or trends.
Reporting of ICSRs is an essential component of pharmacovigilance, and regulatory authorities require that pharmaceutical companies report adverse events associated with their products in a timely and accurate manner. The process of reporting typically involves the submission of periodic safety update reports, as well as ad-hoc reports for significant safety events.
Causality Assessment
Causality assessment is the process of evaluating the relationship between a medical event, such as a disease or adverse drug reaction, and a specific exposure, such as a medication or environmental factor. The purpose of causality assessment is to determine whether the exposure is likely to have caused the event or whether the event is due to other causes.
Causality assessment involves a systematic evaluation of the available evidence, including clinical data, laboratory results, medical history, and other relevant information. The assessment is typically based on a set of criteria, such as the temporal relationship between the exposure and the event, the strength of the association, the presence of alternative explanations, and other factors.
Causality assessment is an important tool in pharmacovigilance, which is the science of monitoring and evaluating the safety of medicines. It is also used in epidemiological research to identify and understand the causes of diseases and other medical events.
Causality assessment is not always straightforward, and there is often a degree of uncertainty involved in the process. However, it is an essential part of evaluating the safety and efficacy of medical treatments and is used by regulatory agencies, healthcare providers, and researchers to make informed decisions about patient care and public health.
AGGREGATE REPORTING IN PHARMACOVIGILANCE
Aggregate reporting in pharmacovigilance refers to the process of collecting and analyzing data from multiple sources, such as clinical trials, post-marketing surveillance, and spontaneous adverse event reporting, to identify patterns or trends in the safety of a drug or medical product. The goal of aggregate reporting is to provide a comprehensive and accurate overview of the safety profile of a drug or medical product, and to identify any potential safety concerns.
Aggregate reports are typically required by regulatory authorities as part of the pharmacovigilance requirements for drug and medical product approval and post-marketing surveillance. These reports are also used by manufacturers to monitor the safety of their products and to make decisions regarding product labeling and risk management.
The most common types of aggregate reports in pharmacovigilance include periodic safety update reports (PSURs), which provide a comprehensive overview of the safety profile of a drug or medical product over a specified time period, and signal detection reports, which identify potential safety signals or concerns based on analysis of adverse event data.
The process of aggregate reporting typically involves the collection and analysis of data from multiple sources, including clinical trials, post-marketing surveillance, and spontaneous adverse event reporting. This data is then analyzed using statistical methods to identify patterns or trends in the safety of the drug or medical product. The results of this analysis are then compiled into a comprehensive report, which includes a summary of the safety profile of the drug or medical product, any identified safety concerns, and recommendations for further monitoring or risk management.
Post-Marketing Surveillance: Monitoring Drug Safety After Approval
Post-marketing surveillance, also known as post-marketing monitoring or pharmacovigilance, is a critical component of drug safety monitoring that occurs after a pharmaceutical product has been approved and is available on the market. It involves the systematic collection, analysis, and evaluation of real-world data to detect and assess any previously unrecognized adverse effects or other drug-related problems. Here are the key aspects of post-marketing surveillance and its role in monitoring drug safety after approval:
Adverse Event Reporting: Post-marketing surveillance relies on the reporting of adverse events (AEs) by healthcare professionals, patients, and pharmaceutical companies. These reports, known as spontaneous or voluntary reports, provide valuable information about potential drug-related issues encountered in real-world clinical practice.
Signal Detection: Post-marketing surveillance aims to detect signals, which are patterns or associations between a drug and an adverse event that may suggest a previously unrecognized safety concern. Signals are identified through various sources, including spontaneous reports, scientific literature, electronic health records, and other healthcare databases.
Data Collection: Post-marketing surveillance collects data from diverse sources, such as individual case safety reports (ICSRs), observational studies, registries, clinical trials, and electronic health records. These sources provide a wealth of real-world data that can help identify safety signals and generate evidence regarding drug safety in broader patient populations.
Risk Assessment: The collected data are analyzed and assessed to evaluate the potential risks associated with a drug. This involves analyzing the frequency, severity, and potential causal relationship between the drug and adverse events. Risk assessment helps determine the magnitude and significance of safety concerns and guides regulatory decisions and risk management strategies.
Benefit-Risk Assessment: Post-marketing surveillance supports ongoing benefit-risk assessments of drugs. It involves weighing the potential benefits of the drug against the identified risks and any additional safety concerns that arise during the post-marketing phase. This assessment ensures that the overall benefit-risk profile of the drug remains favorable and justifies its continued use.
Signal Validation: Signals detected through post-marketing surveillance undergo further investigation and validation to confirm their association with the drug. This may involve conducting additional studies, including observational studies, epidemiological research, and clinical trials, to gather more evidence and evaluate causality.
Role of Biostatistics in Clinical Trials
Biostatistics plays a crucial role in all phases of clinical trials, contributing to the design, analysis, interpretation, and reporting of study results. Biostatisticians collaborate with other researchers, clinicians, and experts to ensure that clinical trials are conducted with scientific rigor and that the data generated are meaningful and valid. Here's a breakdown of the key roles of biostatistics in clinical trials
Good Clinical Practice Guideline – a standard for clinical trials
The Good Clinical Practice (GCP) Guideline stands as a universally recognized standard for the conduct of clinical trials in the field of medical research. GCP sets forth a comprehensive framework of ethical and quality principles to ensure the safety, rights, and well-being of human research participants and the reliability of trial data. Encompassing all stages of clinical research, from study design to reporting of results, GCP serves as a guiding compass, promoting the highest standards of trial conduct, data integrity, and regulatory compliance. By adhering to GCP, researchers, sponsors, and regulatory authorities collaborate to uphold the trust and integrity of clinical trials, thereby fostering the development of safe and efficacious medical interventions for the benefit of patients and public health.
Reporting of ICSR (individual case safety report)
An Individual Case Safety Report (ICSR) is a report of an adverse event or suspected adverse reaction to a medicinal product that has occurred in a patient or study subject. Reporting of ICSRs is a critical component of pharmacovigilance, as it helps to identify and assess potential risks associated with the use of a medicinal product.
The process for reporting an ICSR typically involves the following steps:
Identification of an adverse event or suspected adverse reaction: This may occur through a variety of channels, including spontaneous reports from healthcare professionals or patients, reports from clinical trials or other studies, or signals detected through pharmacovigilance activities.
Collection of information: Once an adverse event or suspected adverse reaction has been identified, information about the event must be collected, including the patient's demographic information, medical history, and details about the adverse event or reaction.
Assessment of causality: The information collected about the adverse event or reaction must be assessed to determine whether there is a causal relationship between the medicinal product and the event.
Completion of the ICSR: Once causality has been established, an ICSR must be completed, typically using a standardized form or electronic system. The ICSR should include all relevant information about the patient, the medicinal product, and the adverse event or reaction.
Submission of the ICSR: The completed ICSR must be submitted to the appropriate regulatory authority, typically through a designated reporting system.
It is important to report ICSRs in a timely and accurate manner, as this helps to ensure that potential risks associated with the use of medicinal products are identified and addressed promptly. Failure to report ICSRs can result in serious consequences, including harm to patients, regulatory action against pharmaceutical companies, and damage to public confidence in the healthcare system.
CSR Automation: Streamlining Clinical Study Reporting
Clinical Study Reports (CSRs) play a pivotal role in communicating the results and findings of clinical trials. The traditional process of creating CSRs is resource-intensive and time-consuming. The integration of automation technologies offers a transformative solution to streamline CSR generation, enhancing efficiency, accuracy, and overall study reporting. This article explores the key aspects, benefits, and considerations associated with CSR automation.
What is an adverse drug reaction and different types of ADRS
An adverse drug reaction (ADR) is any harmful or unintended response to a medication or drug, which occurs at doses normally used for prevention, diagnosis, or treatment of a disease or disorder. ADRs can range from mild symptoms such as a rash or nausea to severe reactions such as organ failure or death. Here are the different types of ADRs:
Type A ADRs: Type A ADRs are predictable and are related to the pharmacological action of the drug. These reactions are usually dose-dependent, and their incidence increases with the drug dose. Common examples include nausea, vomiting, constipation, dizziness, and sedation.
Type B ADRs: Type B ADRs are unpredictable and are not related to the pharmacological action of the drug. These reactions are usually idiosyncratic and occur in only a small percentage of patients. Examples include allergic reactions, drug-induced liver injury, and blood disorders.
Type C ADRs: Type C ADRs are chronic and occur after prolonged use of the drug. These reactions are usually dose-dependent and may lead to long-term damage or injury. Examples include bone loss, adrenal suppression, and Cushing's syndrome.
Type D ADRs: Type D ADRs are delayed reactions and occur after the patient has stopped taking the drug. These reactions are usually related to the long half-life of the drug or its metabolites. Examples include tardive dyskinesia, drug-induced cancer, and teratogenic effects.
Type E ADRs: Type E ADRs are end-of-treatment reactions and occur after the patient has completed a course of treatment with the drug. These reactions are usually related to the withdrawal of the drug and may include symptoms such as rebound hypertension, depression, or anxiety.
Type F ADRs: Type F ADRs are failure of therapy reactions and occur when the drug fails to produce the desired therapeutic effect. These reactions may be due to drug interactions, poor compliance, or underlying disease progression.
Quality Assurance in Clinical Trials
Quality assurance in clinical trials refers to the systematic and planned activities implemented to ensure that the trial is conducted in compliance with applicable regulations, protocols, standard operating procedures (SOPs), and ethical principles. It involves various processes, checks, and measures to monitor, evaluate, and improve the quality of data and the overall conduct of the trial. Here are some key aspects of quality assurance in clinical trials:
Development and Implementation of Quality Management Systems:
Establishing a robust quality management system (QMS) is crucial for ensuring quality in clinical trials. This includes the development and implementation of SOPs, guidelines, and protocols that outline standardized procedures and practices to be followed. The QMS defines the roles, responsibilities, and training requirements for study personnel and provides a framework for quality oversight throughout the trial.
Protocol and Regulatory Compliance:
Quality assurance activities focus on ensuring compliance with the study protocol, applicable regulations, and guidelines. This involves verifying that all study activities and procedures are conducted according to the approved protocol and regulatory requirements. It includes assessing informed consent processes, eligibility criteria, data collection and management practices, adverse event reporting, and adherence to Good Clinical Practice (GCP) guidelines.
Site Selection, Training, and Monitoring:
Quality assurance includes the selection and qualification of investigational sites based on their ability to meet study requirements and conduct trials in compliance with GCP. It involves providing appropriate training to site staff on the protocol, study procedures, data collection, and safety reporting. Regular monitoring visits and site audits are conducted to evaluate compliance, data integrity, and adherence to the protocol and SOPs.
Data Integrity and Management:
Ensuring the accuracy, completeness, and integrity of trial data is a critical aspect of quality assurance. This involves implementing processes to capture, record, and manage data in a consistent and standardized manner. Data validation checks, source data verification, and data reconciliation are performed to detect and resolve data discrepancies or errors. Data management plans and systems are established to maintain data integrity and ensure data security and confidentiality.
Clinical Data Management importance in Clinical Trials
Clinical data management (CDM) is a crucial component of clinical trials that involves the collection, processing, validation, and management of data generated during the course of a clinical study. It plays a vital role in ensuring the accuracy, integrity, and quality of the data collected, which is essential for reliable analysis and interpretation of study results. Here are some key reasons highlighting the importance of clinical data management in clinical trials:
Data Integrity: CDM focuses on maintaining the integrity of the data collected during a clinical trial. This involves applying standardized data collection methods, implementing data validation checks, and ensuring data accuracy, completeness, and consistency. By maintaining data integrity, CDM helps minimize errors, reduce bias, and enhance the reliability and credibility of study findings.
Compliance with Regulatory Requirements: Clinical trials are subject to stringent regulatory guidelines and standards. CDM ensures that the collected data meets these requirements, including adherence to Good Clinical Practice (GCP) guidelines, data privacy regulations, and relevant industry-specific standards. Proper data management practices facilitate regulatory inspections and audits, demonstrating the compliance of the study with applicable regulations.
Efficient Data Handling: CDM streamlines the process of data collection, entry, and management. It involves the development of data collection forms (e.g., electronic Case Report Forms - eCRFs), database design, and data validation procedures. Efficient data handling processes minimize data discrepancies, reduce manual errors, and improve data quality, ultimately leading to more accurate and reliable study results.
Quality Control and Data Cleaning: CDM includes quality control measures to identify and resolve discrepancies, missing data, or inconsistencies in the collected data. Data cleaning activities involve cross-checking and resolving any discrepancies or outliers, ensuring data accuracy and completeness. This process enhances data quality, minimizing the potential impact of data errors on study outcomes.
Database Lock and Analysis: CDM plays a vital role in the database lock process, where the final study database is considered "locked" and no further data modifications are allowed. Database lock is a critical step before statistical analysis and reporting. Proper CDM practices ensure that the database is complete, accurate, and ready for analysis, enabling researchers to generate valid and meaningful results.
Data Security and Confidentiality: CDM incorporates measures to ensure the security and confidentiality of participant data. This includes implementing data access controls, data encryption, and adherence to data protection regulations. Protecting participant privacy and maintaining data security are crucial for building trust with study participants and complying with legal and ethical requirements.
Data Traceability and
Subject Recruitment in Clinical Trials
Subject recruitment is a crucial step in clinical trials as it directly impacts the quality, feasibility, and success of the study. The process involves identifying and enrolling eligible participants who meet the study's inclusion and exclusion criteria. Here are some key considerations for subject recruitment in clinical trials:
Eligibility Criteria: The study's eligibility criteria must be clear and defined in advance to ensure that only eligible participants are enrolled. Inclusion and exclusion criteria may include age, gender, medical history, disease severity, and other factors that are relevant to the study.
Recruitment Methods: There are several recruitment methods that can be used, such as advertising in medical journals, social media, and online forums, collaborating with patient advocacy groups, and working with primary care physicians or specialists who treat patients with the disease or condition under study.
Informed Consent: Potential participants must be provided with all necessary information about the study, including the study's purpose, procedures, risks, and benefits, and be given the opportunity to ask questions before providing informed consent to participate.
Diversity: The study should aim to enroll a diverse population to ensure that the study results are generalizable and applicable to different populations. This includes ensuring adequate representation of different ethnic and racial groups, genders, ages, and other relevant demographic factors.
Patient Engagement: Engaging patients in the recruitment process can help build trust and increase participation rates. This includes involving patient representatives in study design and working with patient advocacy groups to promote the study and recruit participants.
Recruitment Timeline: Recruitment timelines should be realistic and feasible based on the study's objectives and design. Delays in recruitment can significantly impact the study's timeline, cost, and overall feasibility.
Patient Retention: Once enrolled, it is essential to maintain communication with participants to ensure that they remain engaged and continue to participate in the study until completion. This includes providing regular updates, addressing any concerns or questions, and providing support as needed.
Investigator's Brochure - The Road Map for Investigators
The Investigator's Brochure (IB) is a crucial document in the realm of clinical research and drug development. It serves as a comprehensive reference guide for investigators, typically medical professionals conducting clinical trials, and provides essential information about the investigational product (drug or device) being studied. The IB is a road map that helps investigators understand the scientific, medical, and safety aspects of the product, ensuring that they can conduct the trial safely and effectively.
Data security and Privacy in Clinical Research -Compliance and Best Practices...
Data security and privacy are crucial considerations in clinical research to protect the confidentiality and integrity of participant data. Compliance with relevant regulations, such as the General Data Protection Regulation (GDPR) in the European Union and the Health Insurance Portability and Accountability Act (HIPAA) in the United States, is essential. Here are some key aspects of data security and privacy in clinical research, along with best practices to ensure compliance
Integrated pharmacovigilance
Integrated pharmacovigilance refers to the comprehensive and coordinated approach of monitoring, assessing, and managing the safety of pharmaceutical products throughout their lifecycle. It involves the integration of various functions, processes, and stakeholders to ensure the continuous surveillance of the benefits and risks associated with medical products, such as drugs and medical devices. The goal of integrated pharmacovigilance is to enhance patient safety, improve decision-making, and facilitate efficient regulatory oversight.
Institutional review board or Independent ethics committee.pdf
The document discusses the role and responsibilities of an Institutional Review Board or Independent Ethics Committee (IRB/IEC). The IRB/IEC reviews clinical trial protocols and protects the rights, safety, and well-being of study participants. It consists of at least five members with diverse backgrounds and expertise. The IRB/IEC reviews proposed trials, provides guidance to researchers, ensures informed consent, and maintains records for regulatory authorities. Its main purpose is to ethically evaluate clinical trials and safeguard participant protections.
Investigator's Brochure - The Road Map for Investigators
The Investigator's Brochure (IB) is a document that serves as a comprehensive reference manual for investigators who are conducting clinical trials. The IB typically contains information about the investigational product being studied, including its pharmacology, pharmacokinetics, safety and efficacy data, and other relevant information.
The IB is designed to provide investigators with all the information they need to understand the product being studied and its potential risks and benefits. It also provides guidance on how to conduct the clinical trial, including the study design, dosing and administration, monitoring and assessment of safety and efficacy, and other important aspects of the trial.
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine safety monitoring is a critical aspect of pharmacovigilance, particularly given the widespread use of vaccines to prevent infectious diseases. Robust surveillance systems are essential to detect and assess any potential adverse events following vaccination. Here are some key pharmacovigilance strategies employed for vaccine safety monitoring:
Passive Surveillance Systems:
Passive surveillance systems rely on healthcare providers, patients, and other stakeholders to voluntarily report adverse events following vaccination. These reports are collected in databases such as the Vaccine Adverse Event Reporting System (VAERS) in the United States or the Vaccine Adverse Event Surveillance System (VAESS) in other countries. While these systems are valuable for signal detection, they may suffer from underreporting and reporting bias.
Active Surveillance Systems:
Active surveillance involves proactively monitoring a defined population for adverse events following vaccination. This can be done through electronic health records (EHRs), claims databases, and other health data sources. The Vaccine Safety Datalink (VSD) in the United States is an example of an active surveillance system that uses large databases to continuously monitor vaccine safety.
Enhanced Surveillance and Cohort Studies:
Enhanced surveillance involves more intensive monitoring of a specific population or group of interest. Cohort studies are prospective studies that follow a group of vaccinated individuals over time to assess vaccine safety. These studies provide more detailed and controlled data compared to passive or active surveillance.
Comparative Effectiveness Research:
Comparative effectiveness research compares the safety of different vaccines or vaccination schedules. By analyzing large datasets, researchers can evaluate the relative risks and benefits of vaccines and identify any safety concerns.
Signal Detection and Analysis:
Data mining and statistical techniques are used to identify potential safety signals from adverse event reports. Signals are further investigated through in-depth analysis to determine if there is a causal relationship between the vaccine and the adverse event.
Causality Assessment:
Similar to general pharmacovigilance, causality assessment methods (such as the Naranjo Algorithm, WHO-UMC System, and Bayesian methods) are used to evaluate the likelihood of a causal relationship between a vaccine and an adverse event.
Risk Communication and Public Awareness:
Effective communication strategies are crucial to ensure that healthcare providers and the public are informed about vaccine safety. This involves providing clear and accurate information about potential risks and benefits.
Signal detection and their assessment in clinical trials
Signal detection in clinical trials is a crucial aspect of pharmacovigilance that involves identifying potential safety concerns or signals associated with the use of investigational drugs. The process of signal detection is ongoing throughout the life cycle of a drug, from early-phase trials to post-marketing surveillance. Here's an overview of signal detection and the assessment process in clinical trials
Similar to ICSR (individual case safety report) (20)
Post-Marketing Surveillance: Monitoring Drug Safety After Approval
Post-Marketing Surveillance: Monitoring Drug Safety After Approval
Good Clinical Practice Guideline – a standard for clinical trials
Good Clinical Practice Guideline – a standard for clinical trials
CSR Automation: Streamlining Clinical Study Reporting
CSR Automation: Streamlining Clinical Study Reporting
What is an adverse drug reaction and different types of ADRS
What is an adverse drug reaction and different types of ADRS
Clinical Data Management importance in Clinical Trials
Clinical Data Management importance in Clinical Trials
Investigator's Brochure - The Road Map for Investigators
Investigator's Brochure - The Road Map for Investigators
Data security and Privacy in Clinical Research -Compliance and Best Practices...
Data security and Privacy in Clinical Research -Compliance and Best Practices...
Institutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdf
Investigator's Brochure - The Road Map for Investigators
Investigator's Brochure - The Road Map for Investigators
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Signal detection and their assessment in clinical trials
Signal detection and their assessment in clinical trials
More from ClinosolIndia
Role of Drug Regulatory agencies in Clinical Research.
Drug regulatory agencies play a pivotal role in overseeing and regulating clinical research to ensure the safety, efficacy, and quality of pharmaceutical products. Their primary responsibility is to protect public health by evaluating the data generated from clinical trials and determining whether a drug can be approved for marketing and use in patients. Here are some key roles of drug regulatory agencies in clinical research:
Approval and Oversight of Clinical Trials: Regulatory agencies review and approve clinical trial protocols, ensuring that they adhere to ethical and scientific standards. They assess the design, methodology, and objectives of trials to ensure patient safety and the reliability of data generated.
Regulatory Guidance and Standards: These agencies provide guidance and establish regulations governing the conduct of clinical trials, including Good Clinical Practice (GCP) guidelines, which outline standards for trial design, conduct, monitoring, and reporting.
Review and Evaluation of Data: Regulatory agencies review the data collected from clinical trials to assess the safety and efficacy of investigational drugs. They evaluate study results, adverse events, and other relevant information to make informed decisions about drug approval.
Drug Approval and Labeling: Based on the evaluation of clinical trial data, regulatory agencies decide whether to approve a drug for marketing and use. They also determine the appropriate labeling, including indications, dosages, contraindications, and warnings, to ensure safe and effective use by healthcare professionals and patients.
Post-Marketing Surveillance: Regulatory agencies continue to monitor the safety and effectiveness of approved drugs through post-marketing surveillance programs. They collect and analyze real-world data on adverse events and drug utilization to identify potential risks and take appropriate regulatory actions if safety concerns arise.
Enforcement of Regulations: Regulatory agencies enforce compliance with regulatory requirements and take enforcement actions against sponsors, investigators, or manufacturers who fail to adhere to ethical or regulatory standards in clinical research.
International Collaboration: Many regulatory agencies collaborate with counterparts in other countries to harmonize regulatory standards, exchange information, and streamline the drug approval process, facilitating global drug development and access to new therapies.
Data Privacy and consent management .. .
Data privacy and consent management are critical aspects of ensuring that individuals' personal information is handled responsibly and ethically, particularly in healthcare settings where sensitive medical data is involved. Data privacy refers to the protection of personal information from unauthorized access, use, or disclosure, while consent management involves obtaining and managing individuals' permissions for the collection, storage, and processing of their data.
In healthcare, patients entrust providers with their sensitive medical information, expecting that it will be kept confidential and used only for legitimate purposes related to their care. Robust data privacy measures include encryption, access controls, and anonymization techniques to safeguard patient data from unauthorized access or breaches. Additionally, healthcare organizations must adhere to regulatory standards such as HIPAA in the United States or GDPR in the European Union, which outline specific requirements for the protection of patient information and impose penalties for non-compliance.
Consent management plays a crucial role in ensuring that individuals have control over how their data is used. Patients should be informed about the purposes for which their data will be collected and processed, as well as any potential risks or benefits associated with its use. Obtaining informed consent involves providing individuals with clear and transparent information about their privacy rights and giving them the opportunity to consent to or decline the use of their data for specific purposes. Consent management systems help healthcare organizations track and manage patients' consent preferences, ensuring that data is used in accordance with their wishes and legal requirements.
Effective data privacy and consent management practices not only protect individuals' privacy rights but also foster trust and transparency in healthcare relationships. By implementing robust security measures, respecting patients' autonomy, and promoting informed decision-making, healthcare organizations can uphold the principles of data privacy and consent while leveraging data responsibly to improve patient care and outcomes.
Clinical data security and Integrity in Clinical Research
Clinical data security and integrity are paramount in maintaining patient confidentiality, protecting sensitive medical information, and ensuring the reliability of healthcare data. Security measures encompass various strategies and technologies aimed at safeguarding clinical data from unauthorized access, breaches, or manipulation.
Encryption techniques, access controls, and secure authentication mechanisms are commonly employed to restrict access to patient records and prevent unauthorized individuals from viewing or altering sensitive data. Additionally, robust network security protocols, such as firewalls and intrusion detection systems, help safeguard against external threats and cyberattacks targeting healthcare systems.
Pharmacovigilance in Patriatics and Geriatrics
Pharmacovigilance in pediatrics and geriatrics is of paramount importance due to the unique physiological and pharmacokinetic characteristics of these populations. In pediatrics, factors such as rapid growth, organ maturation, and differences in drug metabolism can influence the safety and efficacy of medications. Therefore, monitoring for adverse drug reactions (ADRs), including both known and unexpected effects, is crucial in ensuring the safe use of drugs in children. Additionally, since pediatric patients often receive off-label or unlicensed medications due to limited clinical trials in this population, pharmacovigilance efforts play a critical role in gathering real-world data to inform pediatric drug use.
Presenting- Signal mining in Pharmacovigilance
Signal mining in pharmacovigilance involves the systematic analysis of large datasets to identify potential safety signals associated with medications. It encompasses a variety of computational and statistical methods aimed at detecting patterns or trends that may indicate previously unrecognized adverse drug reactions (ADRs). Signal mining relies on data from sources such as spontaneous reporting systems, electronic health records, clinical trials, and medical literature. Advanced algorithms and data mining techniques, including disproportionality analysis, Bayesian data mining, and machine learning, are employed to sift through vast amounts of data to uncover potential signals of concern. These signals are then subjected to further evaluation to determine their clinical relevance and potential impact on patient safety. By leveraging the power of big data and analytics, signal mining plays a crucial role in enhancing pharmacovigilance efforts, enabling proactive identification and mitigation of medication-related risks, and ultimately contributing to improved patient care and drug safety.
Patient centered Pharmacovigilance .. .
Patient-centered pharmacovigilance represents a pivotal shift in the landscape of healthcare, emphasizing the active involvement of patients in the monitoring and reporting of adverse drug reactions. Unlike traditional pharmacovigilance, which primarily relies on healthcare professionals to identify and document adverse events, this approach recognizes patients as critical stakeholders in ensuring medication safety. By empowering patients to share their experiences, concerns, and observations regarding medication effects, whether positive or negative, healthcare systems can gain a comprehensive understanding of drug safety and efficacy in real-world settings. Patient-centered pharmacovigilance fosters a collaborative partnership between patients, healthcare providers, and regulatory agencies, promoting transparency, accountability, and ultimately, better patient outcomes. Through increased patient engagement and the utilization of patient-reported data, this approach enables healthcare systems to identify potential safety issues earlier, tailor treatment strategies to individual needs, and enhance overall drug safety surveillance efforts.
Introduction to Blogs, Presentations and Review Articles- Noorush Shifa Nizami
Blogs, presentations, and review articles stand as dynamic mediums, each with its unique power to engage, inform, and influence. Blogs, the conversational storytellers; presentations, the visual orchestrators; and review articles, the comprehensive knowledge curators, collectively play pivotal roles in shaping how we share, learn, and explore diverse subjects. This exploration delves into the distinct characteristics and purposes of these forms of communication, unveiling the art of effective expression and knowledge sharing in the digital age.
Patient-Centric Approaches in Precision Medicine Trials: Strategies for Success
Precision medicine, with its focus on tailoring medical treatment to the individual characteristics of each patient, has ushered in a new era in healthcare. Within this paradigm, clinical trials play a pivotal role in testing and validating targeted therapies. This article explores the importance of adopting patient-centric approaches in precision medicine trials and outlines strategies to enhance their success. By prioritizing patient engagement, leveraging digital technologies, and fostering collaborative partnerships, precision medicine trials can not only advance scientific understanding but also ensure that patient perspectives and experiences are integral to the research process.
Collaborative Initiatives: How Patient Advocacy Groups Contribute to the Succ...
Collaborative initiatives involving patient advocacy groups play a crucial role in advancing the success of precision medicine. Precision medicine, also known as personalized medicine, tailors medical treatment and interventions to the characteristics of each patient, considering factors such as genetic makeup, lifestyle, and environment. Patient advocacy groups contribute to the success of precision medicine in several ways:
Raising Awareness and Education:
Patient advocacy groups are instrumental in raising awareness about precision medicine among their communities.
They provide education and resources to patients, caregivers, and the general public, promoting a better understanding of the benefits and implications of precision medicine.
Patient Empowerment:
Advocacy groups empower patients by providing them with information about their conditions and treatment options.
They help patients understand the importance of participating in precision medicine initiatives, including clinical trials and genetic testing.
Supporting Research and Development:
Patient advocacy groups often collaborate with researchers and industry stakeholders to support the development of targeted therapies and diagnostics.
By actively participating in research initiatives, advocacy groups contribute to the identification of genetic markers, biomarkers, and other factors that influence treatment response.
Influencing Policy and Regulation:
Advocacy groups advocate for policies that support the advancement of precision medicine.
They work to ensure that regulations promote patient access to personalized treatments and protect patient rights, privacy, and data security.
Fostering Collaboration:
Patient advocacy groups facilitate collaboration among patients, researchers, healthcare providers, and industry partners.
They create platforms for sharing information, experiences, and best practices, fostering a collaborative environment that accelerates progress in precision medicine.
Clinical Trial Recruitment:
Advocacy groups play a crucial role in recruiting patients for clinical trials related to precision medicine.
Their engagement helps ensure diverse and representative participant populations, leading to more robust and applicable research outcomes.
Feedback and Patient-Centric Approaches:
Advocacy groups provide valuable feedback on the patient experience, preferences, and priorities.
This patient-centric approach helps researchers and healthcare professionals tailor precision medicine strategies to better meet the needs and expectations of the individuals they serve.
Championing Access to Treatments:
Patient advocacy groups work to improve patient access to precision medicine treatments.
They advocate for affordable and equitable access to innovative therapies, ensuring that the benefits of precision medicine are accessible to a broader population.
In summary, patient advocacy groups play a multifaceted role in advancing precision medicine by fostering awareness,
Ethical Dilemmas in Precision Medicine: Navigating the Intersection of Scienc...
The Ethical dilemmas in precision medicine arise from balancing the potential benefits of tailored treatments with concerns about privacy, consent, equity, and the implications of genetic information. These Dilemmas include issues around informed consent for data sharing, ensuring equitable access to precision medicine technologies, and safeguarding against discrimination based on Information. The potential for misuse or unintended consequences further complicate the ethical landscape of precision medicine. The Precision medicine widely used in Data Integration, Biomarkers, Targeted Therapies, predictive modeling, Clinical Decision Support. Precision Medicine improves the Patient outcomes, enhancing treatment efficacy, and reducing healthcare costs by minimizing trial and error in treatment selection. The precision medicine also raises Ethical legal and social complications related to data privacy, consent and equitable access and the potential for Discrimination based on information.
Regulatory Considerations in Precision Medicine: Navigating the Approval Process
Precision medicine, with its focus on tailoring medical treatments to individual characteristics, presents unique regulatory challenges in the drug development and approval process. This ppt delves into the regulatory considerations associated with precision medicine, exploring the key aspects that pharmaceutical and biotechnology companies need to navigate
Emerging Technologies and Tools in Precision Medicine Research
Precision medicine has witnessed significant advancements with the integration of emerging technologies and innovative tools. This abstract explores the current landscape of precision medicine research, focusing on the role of cutting-edge technologies and tools in revolutionizing healthcare approaches.
Precision Medicine in Action: Case Studies and Success Stories
Precision medicine, an innovative approach tailoring medical treatment to individual characteristics, holds great promise for improved patient outcomes. In this paradigm, pharmacovigilance plays a crucial role in monitoring and ensuring the safety of personalized treatments. The integration of big data and artificial intelligence (AI) into pharmacovigilance practices becomes paramount for handling the complexities of individualized therapies and identifying potential safety concerns. This article explores the synergies between big data, AI, and pharmacovigilance in the context of precision medicine.
Harnessing Big Data and Artificial Intelligence for Pharmacovigilance in Prec...
Precision medicine, an innovative approach tailoring medical treatment to individual characteristics, holds great promise for improved patient outcomes. In this paradigm, pharmacovigilance plays a crucial role in monitoring and ensuring the safety of personalized treatments. The integration of big data and artificial intelligence (AI) into pharmacovigilance practices becomes paramount for handling the complexities of individualized therapies and identifying potential safety concerns. This article explores the synergies between big data, AI, and pharmacovigilance in the context of precision medicine.
Integration of Clinical Trial Systems: Enhancing Collaboration and Efficiency
Clinical trials are complex endeavors that involve numerous stakeholders, vast datasets, and intricate processes. To streamline operations, enhance collaboration, and improve efficiency, the integration of clinical trial systems has emerged as a pivotal solution. This strategic approach involves connecting various components, such as electronic data capture (EDC) systems, clinical trial management systems (CTMS), and electronic health records (EHR), fostering a cohesive ecosystem that accelerates the pace of research and ensures data accuracy.
Pharmacovigilance (PV) Companies: Ensuring Drug Safety in Personalized Treatm...
Pharmacovigilance, a critical component of the healthcare and pharmaceutical industry, plays a pivotal role in monitoring and ensuring the safety of drugs. As personalized treatment approaches gain prominence, the responsibilities of PV companies become even more significant. This article explores the key functions of pharmacovigilance companies in the context of personalized medicine, focusing on their role in ensuring drug safety and mitigating potential risks associated with tailored therapeutic interventions.
Adoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
Clinical trials play a pivotal role in advancing medical research and ensuring the efficacy of new treatments. In the context of precision medicine, where therapies are tailored to individual characteristics, adaptive design emerges as a powerful strategy to optimize clinical trial outcomes. This approach deviates from traditional fixed trial designs, allowing for modifications based on accumulating data, thus enhancing efficiency, flexibility, and the likelihood of success in precision medicine endeavors.
Artificial Intelligence In Clinical Trial
Clinical trials are a cornerstone of medical research, paving the way for new treatments and advancements in healthcare. In recent years, Artificial Intelligence (AI) has emerged as a transformative force, reshaping the landscape of clinical trials. This article explores the various ways in which AI is revolutionizing the design, execution, and analysis of clinical trials.
Emerging Technologies Shaping the Future of Precision Medicine
Precision medicine, with its focus on tailoring healthcare interventions to individual characteristics, is undergoing a transformative evolution propelled by emerging technologies. From advanced genomic tools to artificial intelligence, these technologies are revolutionizing our ability to understand, diagnose, and treat diseases at an unprecedented level of specificity. This article explores the key emerging technologies shaping the future of precision medicine.
Innovations in Liquid Biopsies for Precision Cancer Diagnosis
Precision medicine, with its focus on tailoring medical interventions to individual characteristics, benefits significantly from the integration of machine learning (ML) algorithms for predictive analytics. These algorithms analyze complex datasets, identify patterns, and generate predictions that inform personalized treatment strategies. This article explores the diverse applications of ML in precision medicine, highlighting the key algorithms driving predictive analytics in this transformative field.
More from ClinosolIndia (20)
Role of Drug Regulatory agencies in Clinical Research.
Role of Drug Regulatory agencies in Clinical Research.
Clinical data security and Integrity in Clinical Research
Clinical data security and Integrity in Clinical Research
Introduction to Blogs, Presentations and Review Articles- Noorush Shifa Nizami
Introduction to Blogs, Presentations and Review Articles- Noorush Shifa Nizami
Patient-Centric Approaches in Precision Medicine Trials: Strategies for Success
Patient-Centric Approaches in Precision Medicine Trials: Strategies for Success
Collaborative Initiatives: How Patient Advocacy Groups Contribute to the Succ...
Collaborative Initiatives: How Patient Advocacy Groups Contribute to the Succ...
Ethical Dilemmas in Precision Medicine: Navigating the Intersection of Scienc...
Ethical Dilemmas in Precision Medicine: Navigating the Intersection of Scienc...
Regulatory Considerations in Precision Medicine: Navigating the Approval Process
Regulatory Considerations in Precision Medicine: Navigating the Approval Process
Emerging Technologies and Tools in Precision Medicine Research
Emerging Technologies and Tools in Precision Medicine Research
Precision Medicine in Action: Case Studies and Success Stories
Precision Medicine in Action: Case Studies and Success Stories
Harnessing Big Data and Artificial Intelligence for Pharmacovigilance in Prec...
Harnessing Big Data and Artificial Intelligence for Pharmacovigilance in Prec...
Integration of Clinical Trial Systems: Enhancing Collaboration and Efficiency
Integration of Clinical Trial Systems: Enhancing Collaboration and Efficiency
Pharmacovigilance (PV) Companies: Ensuring Drug Safety in Personalized Treatm...
Pharmacovigilance (PV) Companies: Ensuring Drug Safety in Personalized Treatm...
Adoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
Adoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
Emerging Technologies Shaping the Future of Precision Medicine
Emerging Technologies Shaping the Future of Precision Medicine
Innovations in Liquid Biopsies for Precision Cancer Diagnosis
Innovations in Liquid Biopsies for Precision Cancer Diagnosis
Recently uploaded
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Our aim is to organise conscious gatherings and retreats for open and inquisitive minds and souls, with and without the assistance of sacred plants.
Hypotension and role of physiotherapy in it
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
The Power of Superfoods and Exercise.pdf
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...Ear Solutions (ESPL)
Binaural hearing using two hearing aids instead of one offers numerous advantages, including improved sound localization, enhanced sound quality, better speech understanding in noise, reduced listening effort, and greater overall satisfaction. By leveraging the brain’s natural ability to process sound from both ears, binaural hearing aids provide a more balanced, clear, and comfortable hearing experience. If you or a loved one is considering hearing aids, consult with a hearing care professional at Ear Solutions hearing aid clinic in Mumbai to explore the benefits of binaural hearing and determine the best solution for your hearing needs. Embracing binaural hearing can lead to a richer, more engaging auditory experience and significantly improve your quality of life.
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
Innovative Minds France's Most Impactful Healthcare Leaders.pdf
This edition features a handful of Innovative Minds: France's Most Impactful Healthcare Leaders that are leading us into a better future.
Hypertension and it's role of physiotherapy in it.
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
The "Comprehensive Rainy Season Advisory: Safety and Preparedness Tips" offers essential guidance for navigating rainy weather conditions. It covers strategies for staying safe during storms, flood prevention measures, and advice on preparing for inclement weather. This advisory aims to ensure individuals are equipped with the knowledge and resources to handle the challenges of the rainy season effectively, emphasizing safety, preparedness, and resilience.
U Part Wigs_ A Natural Look with Minimal Effort Jokerwigs.in.pdf
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
Pediatric Emergency Care for Children | Apollo Hospital
Pediatric Emergency Care for Children | Apollo HospitalApollo 24/7 Adult & Paediatric Emergency Services
At Apollo Hospital, Lucknow, U.P., we provide specialized care for children experiencing dehydration and other symptoms. We also offer NICU & PICU Ambulance Facility Services. Consult our expert today for the best pediatric emergency care.
For More Details:
Map: https://cutt.ly/BwCeflYo
Name: Apollo Hospital
Address: Singar Nagar, LDA Colony, Lucknow, Uttar Pradesh 226012
Phone: 08429021957
Opening Hours: 24X7NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
Bath patient Fundamental of Nursing.pptx
This is presentation about how to bath a patient.
It is a fundamental of nursing.
CCSN_June_06 2024_jones. Cancer Rehabpptx
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
FACIAL NERVE
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
Discover the groundbreaking advancements in stem cell therapy by R3 Stem Cell, offering new hope for women with ovarian failure. This innovative treatment aims to restore ovarian function, improve fertility, and enhance overall well-being, revolutionizing reproductive health for women worldwide.
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
Christina Spears, breast cancer genetic counselor at the Ohio State University Comprehensive Cancer Center, joined us for the MBC Support Group for Black Women to discuss the importance of genetic testing in communities of color and answer pressing questions.
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
Recently uploaded (20)
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
Innovative Minds France's Most Impactful Healthcare Leaders.pdf
Innovative Minds France's Most Impactful Healthcare Leaders.pdf
Hypertension and it's role of physiotherapy in it.
Hypertension and it's role of physiotherapy in it.
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
U Part Wigs_ A Natural Look with Minimal Effort Jokerwigs.in.pdf
U Part Wigs_ A Natural Look with Minimal Effort Jokerwigs.in.pdf
Pediatric Emergency Care for Children | Apollo Hospital
Pediatric Emergency Care for Children | Apollo Hospital
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
ICSR (individual case safety report)
- 1. Welcome INDIVIDUAL CASE SAFETY REPORT Student’s Name – Prathamesh Bhaskar Golapkar Student’s Qualification - MSc Student ID – CSRPL_STD_IND_HYD_ONL/CLS_027/022023 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch
- 2. Index • What is ICSR ? • A Valid ICSR contains • Steps involved in ICSR • ISCR Collections • Case processing • Data Entry • Points to remember 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch 2
- 3. 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch 3 ICSR is Format/Content Related to Medical product at specific point of time. For reporting ADR occur in single patient
- 4. A Valid ICSR contain atleast : 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch 4 1 Identifiable Reporter 1 Identifiable Patient 1 Suspected A/E 1 Suspected Medicinal Product
- 5. Steps involved in ICSR 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch 5 ICSR Collection Regulatory Submission Medical Review Quality Review Data Entry and Case Processing Triage
- 6. ICSR Collections : 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch 6
- 7. Case Processing : 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch 7 Check for duplicate and Valid ICSR After receipt of SAE forms Drug Safety Associate
- 8. Data Entry : 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch Source of Data Patient details Details related to Suspected ADR Reporter details Suspected Medicinal Product Finally, Narrative writing
- 9. 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch 9 Quality Review team checks for any Data Entry error If Issue found, form resend to Data Entry team for corrections. If no issue found, Case forwarded to Medical Review team.
- 10. 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch 10 Medical review Physician Team ensures that all Medical aspects were address properly Finally, Regulatory submission.
- 11. 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch 11 Points to Remember : Non-Medically Confirmed Case If SAE is reported by non-health care professional like Patient. Medically Confirmed Case If SAE is reported by non-health care professional like Doctor, Pharmacist, Nurse.
- 12. Thank You! www.clinosol.com (India | Canada) 9121151622/623/624 info@clinosol.com 5/5/2023 www.clinosol.com | follow us on social media @clinosolresearch 12